What Happens After Baricitinib Treatment Stops? New Data on Long-Term Outcomes

The BANDIT trial previously showed that baricitinib—an oral immunosuppressive medication—could preserve insulin-producing beta cells in newly diagnosed Type 1 diabetes. During the 48-week treatment period, people taking baricitinib needed less insulin and had better blood sugar control than those on placebo. These results raised important questions: Do the benefits stick around after you stop taking the drug?

Researchers followed 88 trial participants for an additional 48 weeks after baricitinib treatment ended at week 48. They measured beta cell function using C-peptide levels (a marker of how much insulin your own pancreas is still making), blood sugar control, and immune cell changes.

Six months after stopping baricitinib, participants who had received the active drug still showed better C-peptide levels than those on placebo. However, by the one-year mark, this difference had largely faded away. C-peptide levels in the baricitinib group had declined significantly from where they were mid-follow-up.

One noteworthy finding: adults who received baricitinib maintained better beta cell preservation after the drug was stopped, while children showed more decline relative to their baseline. This suggests that age may influence how long-lasting the treatment's effects are—an important distinction for understanding which populations might benefit most.

When researchers compared insulin requirements, HbA1c (average blood sugar over three months), and continuous glucose monitor data at the one-year follow-up, there were no meaningful differences between those who had received baricitinib and those on placebo. Both groups managed their diabetes similarly by that point.

The immune system changes that were visible while taking baricitinib—specifically, reductions in certain disease-fighting T cells—also reversed after the medication stopped. This suggests the drug's immunological effects are temporary rather than permanently reshaping immunity.

This follow-up study shows that baricitinib's benefits are not permanent after stopping treatment. However, it doesn't tell us whether a longer treatment course, retreatment, or combination with other approaches might produce more durable results. Baricitinib remains a tool that may delay beta cell loss during the critical early months after diagnosis, but it is not a long-term solution on its own.

Source: Diabetes care. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.